Search

Displaying all 6 results
DrugBest match

Pazopanib

go.drugbank.com/drugs/DB06589
ApprovedInvestigational

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

  1. Pathway

    Pazopanib Action Pathway

    smpdb.ca/view/SMP0126899
    Drug action

    Pazopanib is an antineoplastic agent utilized for treating advanced renal cell cancer and advanced soft tissue sarcoma in patients who have undergone prior chemotherapy. … targeting vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-alpha, PDGFR-beta), and c-kit, which are integral to the angiogenesis pathway, pazopanib

    Drugs: Calcium · Pazopanib
  2. Indication

    Advanced Thyroid cancer

    go.drugbank.com/conditions/DBCOND0023292
    Drugs: Axitinib · Pazopanib
  3. Indication

    Advanced Soft Tissue Sarcoma

    go.drugbank.com/conditions/DBCOND0060596
    Drugs: Dacarbazine · Paclitaxel · Pazopanib · Vinblastine
  4. Indication

    Advanced Renal Cell Carcinoma

    go.drugbank.com/conditions/DBCOND0032596
    Drugs: Avelumab · Axitinib · Belzutifan · Cabozantinib · Hyaluronidase (human recombinant) · Lenvatinib +6 more
  5. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    [A262097] For the small-molecule approach, most earlier generations of VEGFR inhibitors such as [sunitinib], [sorafenib], [regorafenib], and [pazopanib] have poor selectivity, thus increasing the risk